Saito T
Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Gan To Kagaku Ryoho. 1988 Mar;15(3):549-54.
Carboquone (CQ) is an anticancer alkylating agent synthesized and developed by Arakawa et al. (Sankyo Co, Ltd.) in 1970, having chemical structure, 2,5-bis-(1-aziridinyl)-3-(2-carbamoyloxy-1-methoxyethyl)-6-methyl- 1,4- benzoquinone. The antitumor efficacies of CQ were reported as excellent, however, the side effects are considerably strong. For the purpose to increase the effectiveness and to eliminate the side effect, various treatment regimen with CQ have been reported. Combination chemotherapies including CQ and cis-Platinum etc. have been reported to increase the antineoplastic activity and CQ combined with immunopotentiator or prednisone have been reported to diminish the side effects. The regimens of PPQ therapy in our department is as follows. CQ is given 7 mg/m2 iv on day 1; cis-Platinum 20 mg/body, drip infusion on day 1-5. Prednisone 3.0 mg p.o. on day 1-5. The response rate found in this regimen was about 30% so far. Antitumor spectrum of this drug has been reported to become broad.
卡波醌(CQ)是荒川等人(三共株式会社)于1970年合成并研发的一种抗癌烷化剂,其化学结构为2,5-双(1-氮丙啶基)-3-(2-氨基甲酰氧基-1-甲氧基乙基)-6-甲基-1,4-苯醌。据报道,CQ的抗肿瘤疗效极佳,然而,其副作用相当严重。为了提高疗效并消除副作用,已报道了多种使用CQ的治疗方案。据报道,包括CQ与顺铂等的联合化疗可提高抗肿瘤活性,而CQ与免疫增强剂或泼尼松联合使用可减少副作用。我们科室的PPQ治疗方案如下。第1天静脉注射CQ 7 mg/m²;第1 - 5天顺铂20 mg/人,静脉滴注。第1 - 5天口服泼尼松3.0 mg。到目前为止,该方案的有效率约为30%。据报道,这种药物的抗肿瘤谱已变广。